In a quiet lab in Joondalup, Western Australia, Professor Wei Wang and his team at Edith Cowan University are decoding a hidden language written in sugar. These aren’t the sweet crystals in your kitchen, but intricate chains of molecules called glycans that coat every cell in your body—silent messengers now revealing secrets about disease up to a decade before symptoms appear. For years, glycans were dismissed as mere biological decoration, passive bystanders in the grand machinery of human health. But Wang’s groundbreaking research, published in Nature Chemical Biology, proves they are anything but. They are dynamic, responsive, and, most importantly, predictive.
This discovery matters because it could shift medicine from reaction to prevention. While DNA offers a static blueprint of inherited risk, glycans provide a real-time health dashboard, constantly reshaped by lifestyle, environment, and underlying illness. The study found that specific patterns in blood glycans can forecast the onset of type 2 diabetes as early as 10 years before diagnosis—opening a critical window for intervention. At a time when chronic diseases strain healthcare systems worldwide, the ability to act early could save millions of lives and billions in treatment costs.
Wang leads the Suboptimal Health and Glycomics research group at ECU’s Center for Precision Health, where his team analyzed large glycomics datasets to uncover consistent, measurable patterns linked to disease development. Their work shows that glycans actively regulate immune function and disease progression, influenced by a unique mix of genetics, hormones, and environmental exposures. This makes each person’s glycome—a term for their full set of glycans—deeply individual, offering a new frontier in personalized medicine. "The glycome gives us a live window into how the body is changing," Wang said. "DNA can’t do that."
The implications are profound. One day, a routine blood test could map your glycan profile, alerting doctors to rising risks for diabetes, cancer, or autoimmune disorders long before traditional markers appear. Treatments could be tailored not just to your genes, but to your body’s current biological state. Yet, as promising as this is, the team emphasizes caution. Widespread clinical use will require larger, long-term studies and global standardization of glycan testing methods.
Still, the momentum is building. With collaborators like Maja Pučić-Baković contributing to the foundational science, the field of glycomics is stepping into the spotlight. This isn’t just a new test—it’s a new way of seeing health. As Wang puts it, "We’re at a turning point. If we get this right, it could transform how we diagnose and treat disease."
And somewhere in Joondalup, the sugar code is starting to speak.